CN113413395A - Composition containing pinoresinol diglucoside and preparation method and application thereof - Google Patents
Composition containing pinoresinol diglucoside and preparation method and application thereof Download PDFInfo
- Publication number
- CN113413395A CN113413395A CN202110733999.0A CN202110733999A CN113413395A CN 113413395 A CN113413395 A CN 113413395A CN 202110733999 A CN202110733999 A CN 202110733999A CN 113413395 A CN113413395 A CN 113413395A
- Authority
- CN
- China
- Prior art keywords
- parts
- pinoresinol diglucoside
- distilled water
- polysaccharide
- diglucoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- ZJSJQWDXAYNLNS-UHFFFAOYSA-N (+) pinoresinol-4,4'-di-O-beta-D-glucopyranoside Natural products COC1=CC(C2C3C(C(OC3)C=3C=C(OC)C(OC4C(C(O)C(O)C(CO)O4)O)=CC=3)CO2)=CC=C1OC1OC(CO)C(O)C(O)C1O ZJSJQWDXAYNLNS-UHFFFAOYSA-N 0.000 title claims abstract description 62
- ZJSJQWDXAYNLNS-FUPWJLLWSA-N (2s,3r,4s,5s,6r)-2-[4-[(3s,3ar,6s,6ar)-6-[3-methoxy-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-3-yl]-2-methoxyphenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound COC1=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC=3)CO2)=CC=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZJSJQWDXAYNLNS-FUPWJLLWSA-N 0.000 title claims abstract description 62
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 46
- 150000004676 glycans Chemical class 0.000 claims abstract description 44
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 44
- 239000005017 polysaccharide Substances 0.000 claims abstract description 44
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 23
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 23
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 23
- KOWMJRJXZMEZLD-UHFFFAOYSA-N syringaresinol Chemical compound COC1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(OC)C(O)=C(OC)C=3)CO2)=C1 KOWMJRJXZMEZLD-UHFFFAOYSA-N 0.000 claims abstract description 22
- LVUPFEOCDSHRBL-UHFFFAOYSA-N syringaresinol Natural products COc1cccc(OC)c1C2OCC3C2COC3c4c(OC)cccc4OC LVUPFEOCDSHRBL-UHFFFAOYSA-N 0.000 claims abstract description 22
- DBTMGCOVALSLOR-AXAHEAMVSA-N galactotriose Natural products OC[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](CO)O[C@@H](O[C@H]3[C@@H](O)[C@H](O)O[C@@H](CO)[C@@H]3O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O DBTMGCOVALSLOR-AXAHEAMVSA-N 0.000 claims abstract description 21
- FZWBNHMXJMCXLU-YRBKNLIBSA-N manninotriose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-YRBKNLIBSA-N 0.000 claims abstract description 21
- 241000221377 Auricularia Species 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 13
- -1 bergamotol lactone Chemical class 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 76
- 239000012153 distilled water Substances 0.000 claims description 62
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 30
- 239000002904 solvent Substances 0.000 claims description 23
- 239000002244 precipitate Substances 0.000 claims description 18
- 239000002202 Polyethylene glycol Substances 0.000 claims description 17
- 229920001223 polyethylene glycol Polymers 0.000 claims description 17
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims description 15
- 229940070765 laurate Drugs 0.000 claims description 15
- 239000003480 eluent Substances 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 238000009835 boiling Methods 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 6
- 230000001376 precipitating effect Effects 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 238000002137 ultrasound extraction Methods 0.000 claims description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 2
- LHAOFBCHXGZGOR-NAVBLJQLSA-N alpha-D-Manp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1 LHAOFBCHXGZGOR-NAVBLJQLSA-N 0.000 claims description 2
- 229940075529 glyceryl stearate Drugs 0.000 claims description 2
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 238000002604 ultrasonography Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 230000002411 adverse Effects 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- BGEBZHIAGXMEMV-UHFFFAOYSA-N 5-methoxypsoralen Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC BGEBZHIAGXMEMV-UHFFFAOYSA-N 0.000 description 12
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 239000011259 mixed solution Substances 0.000 description 9
- 210000000988 bone and bone Anatomy 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 244000028550 Auricularia auricula Species 0.000 description 6
- 235000000023 Auricularia auricula Nutrition 0.000 description 6
- DBMJZOMNXBSRED-UHFFFAOYSA-N Bergamottin Natural products O1C(=O)C=CC2=C1C=C1OC=CC1=C2OCC=C(C)CCC=C(C)C DBMJZOMNXBSRED-UHFFFAOYSA-N 0.000 description 6
- 229960002045 bergapten Drugs 0.000 description 6
- KGZDKFWCIPZMRK-UHFFFAOYSA-N bergapten Natural products COC1C2=C(Cc3ccoc13)C=CC(=O)O2 KGZDKFWCIPZMRK-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- 230000037182 bone density Effects 0.000 description 4
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 description 3
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 150000002596 lactones Chemical class 0.000 description 3
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000112528 Ligusticum striatum Species 0.000 description 2
- 102100031475 Osteocalcin Human genes 0.000 description 2
- 108090000573 Osteocalcin Proteins 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000004097 bone metabolism Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- JGINTSAQGRHGMG-NLJYZETGSA-N (z)-5-[(1s,5s,6r)-4,6-dimethyl-6-bicyclo[3.1.1]hept-3-enyl]-2-methylpent-2-en-1-ol Chemical compound C1[C@@H]2[C@@](CC/C=C(CO)/C)(C)[C@H]1CC=C2C JGINTSAQGRHGMG-NLJYZETGSA-N 0.000 description 1
- 240000000031 Achyranthes bidentata Species 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241001148494 Cibotium Species 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 240000004270 Colocasia esculenta var. antiquorum Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000209020 Cornus Species 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 241000241550 Cyathula Species 0.000 description 1
- 241000123589 Dipsacus Species 0.000 description 1
- 241001116742 Drynaria Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000208688 Eucommia Species 0.000 description 1
- 244000268590 Euryale ferox Species 0.000 description 1
- 235000006487 Euryale ferox Nutrition 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 244000116484 Inula helenium Species 0.000 description 1
- 235000002598 Inula helenium Nutrition 0.000 description 1
- 241000488974 Loranthus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 240000004980 Rheum officinale Species 0.000 description 1
- 235000008081 Rheum officinale Nutrition 0.000 description 1
- 241001278833 Rosa laevigata Species 0.000 description 1
- 235000000661 Rosa laevigata Nutrition 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 244000107975 Strychnos nux-vomica Species 0.000 description 1
- 240000004824 Trimezia steyermarkii Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 239000009136 dragon's blood Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 201000000916 idiopathic juvenile osteoporosis Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Sustainable Development (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of medicine preparation, and particularly relates to a composition containing pinoresinol diglucoside, and a preparation method and application thereof. A composition containing pinoresinol diglucoside comprises the following components: pinoresinol diglucoside, syringaresinol, Auricularia polysaccharide, gamma-aminobutyric acid, manninotriose and bergamotol lactone. The composition has good therapeutic effect on osteoporosis, and has the advantages of simple preparation method, low adverse side effect, and low cost.
Description
Technical Field
The invention belongs to the technical field of medicine preparation, and particularly relates to a composition containing pinoresinol diglucoside, and a preparation method and application thereof.
Background
Osteoporosis (osteoporotis) is a systemic bone disease in which bone fracture is easily caused by a decrease in bone density and bone mass due to various causes, a destruction of bone microarchitecture, and an increase in bone fragility. Osteoporosis is divided into primary and secondary categories. Primary osteoporosis is further classified into postmenopausal osteoporosis, senile osteoporosis and idiopathic osteoporosis.
There are a variety of methods for treating osteoporosis in the prior art. For example, the chinese patent application CN1583069A discloses a medicine for treating osteoporosis, which is composed of the following raw materials in parts by weight: 8-12 parts of drynaria rhizome, 4-7 parts of eucommia bark, 4-7 parts of parasitic loranthus, 2-4 parts of cibotium rhizome, 3-6 parts of ligusticum wallichii, 3-5 parts of angelica sinensis, 4-6 parts of safflower, 3-5 parts of bighead atractylodes rhizome and 6-10 parts of medicinal cyathula root. The medicine is prepared by selecting medicines according to the theory of 'kidney governs bone and produces marrow' in the traditional Chinese medicine, mainly tonifying liver and kidney, giving consideration to treatment methods of tonifying spleen and stomach, promoting blood circulation and removing blood stasis, and the like. The clinical and animal in-vivo and in-vitro experimental studies show that the medicine for treating osteoporosis can fundamentally adjust bone metabolism and convert the bone metabolism to a normal balance direction.
Chinese patent application CN1079160A discloses a Chinese herbal medicine which is very effective in treating osteoporosis broken bone and consists of 18 Chinese herbal medicines of agilawood, saffron, elecampane, ligusticum wallichii, cassia twig, angelica dahurica, pseudo-ginseng, teasel root, ground beeltle, rhizoma drynariae, processed nux vomica, achyranthes bidentata, cucumber seed, chicken bone, rheum officinale, native copper, borneol and dragon's blood.
Chinese patent application CN111714577A discloses a medicine "zhengyuan gutai" for preventing and treating osteoporosis and its preparation method. It is a micromolecule traditional Chinese medicine which is prepared by pure natural medicinal materials such as cornus, gordon euryale seed, cherokee rose, yam, goat bone, ox tendon, deer tendon and the like by using biotechnology and takes compound amino acid as main material; has effects in nourishing yin, warming yang, removing blood stasis, dredging meridians, invigorating kidney, and strengthening bone.
Most of the existing methods for treating osteoporosis have limited treatment effect, and meanwhile, a part of Chinese herbal medicine formula has more components, wherein a plurality of impurities exist, so that the medicine effect is influenced, the utilization rate of the medicine is greatly reduced, and on the other hand, side effects are possibly generated to be not beneficial to the health.
The invention aims to research a composition containing pinoresinol diglucoside for treating osteoporosis, which has the advantages of small side effect, low cost and good effect, and can effectively solve the problems.
Disclosure of Invention
In order to overcome the technical problems, the invention provides a composition containing pinoresinol diglucoside and a preparation method and application thereof; the composition has good therapeutic effect on osteoporosis, and has the advantages of simple preparation method, low adverse side effect, and low cost.
In order to achieve the above purpose, the technical scheme provided by the invention is as follows:
a composition containing pinoresinol diglucoside comprises the following components:
pinoresinol diglucoside, syringaresinol, Auricularia polysaccharide, gamma-aminobutyric acid, manninotriose and bergamotol lactone.
Preferably, the composition comprises the following components in parts by weight:
10-20 parts of pinoresinol diglucoside, 1-5 parts of syringaresinol, 5-10 parts of agaric polysaccharide, 1-5 parts of gamma-aminobutyric acid, 1-10 parts of manninotriose and 5-15 parts of bergamoolide.
Preferably, the composition comprises the following components in parts by weight:
12-16 parts of pinoresinol diglucoside, 3-5 parts of syringaresinol, 7-9 parts of agaric polysaccharide, 2-4 parts of gamma-aminobutyric acid, 4-8 parts of manninotriose and 10-12 parts of bergamoolide.
Preferably, the preparation method of the agaric polysaccharide comprises the following steps:
(1) cleaning Auricularia, soaking, homogenizing, extracting in distilled water, and filtering to obtain primary extractive solution and residue;
(2) adding distilled water into the filter residue, and performing ultrasonic extraction to obtain a secondary extracting solution;
(3) mixing the primary and secondary extractive solutions, concentrating under reduced pressure, and precipitating with ethanol; preparing alcohol precipitate;
(4) dissolving the alcohol precipitate in water, treating the alcohol precipitate by sephadexG-100 gel column, eluting by using ethyl acetate, collecting ethyl acetate eluent, eluting by using distilled water, and collecting distilled water eluent; adding distilled water into ethyl acetate eluate for extraction, mixing the separated water phase with distilled water eluate, and concentrating to obtain Auricularia polysaccharide.
Preferably, in step (1), the extraction is performed at 60-80 deg.C for 30-60min and boiling for 1-2 h.
Preferably, in the step (2), the power of the ultrasound is 80-100W; the extraction time is 30-60 min.
Another object of the present invention is to provide a method for preparing the composition containing pinoresinol diglucoside, comprising the steps of:
dissolving gamma-aminobutyric acid in distilled water, adding solubilizer, and dispersing pinoresinol diglucoside, syringaresinol, Auricularia polysaccharide, mannotriose, and bergamoolide in distilled water to obtain mixture.
Preferably, the solubilizer is any one or more of propylene glycol, polyethylene glycol laurate and polyethylene glycol glyceryl stearate.
Preferably, the solubilizer is a mixture of propylene glycol and polyethylene glycol laurate, wherein the mass ratio of the propylene glycol to the polyethylene glycol laurate is 1-3: 1.
Preferably, the polyethylene glycol laurate has a relative molecular weight of 600-1000.
Preferably, the mass concentration of the solubilizer in distilled water is 1-5%.
The invention also aims to provide application of the composition containing pinoresinol diglucoside in preparing a medicament for preventing and treating osteoporosis.
The invention also aims to provide a pharmaceutical preparation which comprises the composition containing pinoresinol diglucoside and pharmaceutically common auxiliary materials.
Compared with the prior art, the invention has the technical advantages that:
(1) the composition containing pinoresinol diglucoside provided by the invention can effectively prevent and treat osteoporosis.
(2) The agaric polysaccharide can promote blood circulation, has the effect of improving the immunity of the organism, can effectively promote the absorption of calcium of the organism and improve osteoporosis; meanwhile, the pinoresinol diglucoside, the agaric polysaccharide and the gamma-aminobutyric acid have good synergistic effect, and can effectively prevent and treat osteoporosis and enhance the bone density.
(3) Syringaresinol, manninotriose and bergamotol have good synergistic effect, and can effectively promote the bone strength, immunity, fatigue resistance and other effects of the pinoresinol diglucoside.
(4) SephadexG100 is used in the extraction process of the agaric polysaccharide, so that the separation of the polysaccharide from protein and other impurity small molecules can be effectively promoted, and the purification of the agaric polysaccharide is promoted.
(5) According to the invention, the agaric is extracted by combining water extraction and ultrasonic extraction, so that polysaccharide components in the agaric can be effectively extracted, and the utilization rate of the agaric is improved.
(6) When the mixed solution is prepared, the mixture of the propylene glycol and the polyethylene glycol laurate is selected as the solubilizer, so that on one hand, the dissolubility of each component in water can be effectively promoted, and on the other hand, when the auxiliary materials are added to prepare the preparation, the utilization rate of the effective components can be improved, and the effect can be effectively exerted.
Detailed Description
The present invention will be described below with reference to specific examples to make the technical aspects of the present invention easier to understand and grasp, but the present invention is not limited thereto. The experimental methods described in the following examples are all conventional methods unless otherwise specified; the reagents and materials are commercially available, unless otherwise specified.
Example 1
The composition containing pinoresinol diglucoside comprises the following components in parts by weight:
13 parts of pinoresinol diglucoside, 4 parts of syringaresinol, 8 parts of agaric polysaccharide, 3 parts of gamma-aminobutyric acid, 5 parts of manninotriose and 11 parts of bergamoolide.
The preparation method of the agaric polysaccharide comprises the following steps:
(1) cleaning Auricularia, soaking, homogenizing, extracting with distilled water at 70 deg.C for 40min, boiling for 1.5 hr, and filtering to obtain primary extractive solution and residue;
(2) adding distilled water into the filter residue, and performing ultrasonic extraction for 50min with ultrasonic power of 80W to obtain secondary extract;
(3) mixing the primary and secondary extractive solutions, concentrating under reduced pressure, and precipitating with ethanol; preparing alcohol precipitate;
(4) dissolving the alcohol precipitate in water, treating the alcohol precipitate by sephadexG-100 gel column, eluting by using ethyl acetate, collecting ethyl acetate eluent, eluting by using distilled water, and collecting distilled water eluent; adding distilled water into ethyl acetate eluate for extraction, mixing the separated water phase with distilled water eluate, and concentrating to obtain Auricularia polysaccharide.
The preparation method of the composition containing pinoresinol diglucoside comprises the following steps:
dissolving gamma-aminobutyric acid in 200 parts of distilled water, adding a mixture of 2:1 propylene glycol and polyethylene glycol laurate (M is 800) as a solubilizer, wherein the mass concentration of the solubilizer in the distilled water is 2%, and then dispersing pinoresinol diglucoside, syringaresinol, agaric polysaccharide, manninotriose and bergapten in the distilled water to prepare a mixed solution of the composition.
Example 2
The composition containing pinoresinol diglucoside comprises the following components in parts by weight:
10 parts of pinoresinol diglucoside, 1 part of syringaresinol, 5 parts of agaric polysaccharide, 1 part of gamma-aminobutyric acid, 10 parts of manninotriose and 15 parts of bergamoolide.
The preparation method of the agaric polysaccharide comprises the following steps:
(1) cleaning Auricularia, soaking, homogenizing, extracting with distilled water at 60 deg.C for 60min, boiling for 1 hr, and filtering to obtain primary extractive solution and residue;
(2) adding distilled water into the filter residue, and performing ultrasonic extraction for 30min with ultrasonic power of 100W to obtain secondary extract;
(3) mixing the primary and secondary extractive solutions, concentrating under reduced pressure, and precipitating with ethanol; preparing alcohol precipitate;
(4) dissolving the alcohol precipitate in water, treating the alcohol precipitate by sephadexG-100 gel column, eluting by using ethyl acetate, collecting ethyl acetate eluent, eluting by using distilled water, and collecting distilled water eluent; adding distilled water into ethyl acetate eluate for extraction, mixing the separated water phase with distilled water eluate, and concentrating to obtain Auricularia polysaccharide.
The preparation method of the composition containing pinoresinol diglucoside comprises the following steps:
dissolving gamma-aminobutyric acid in 200 parts of distilled water, adding a mixture of 1:1 propylene glycol and polyethylene glycol laurate (M600) as a solubilizer, wherein the mass concentration of the solubilizer in the distilled water is 5%, and dispersing pinoresinol diglucoside, syringaresinol, agaric polysaccharide, manninotriose and bergapten in the distilled water to prepare a mixed solution of the composition.
Example 3
The composition containing pinoresinol diglucoside comprises the following components in parts by weight:
20 parts of pinoresinol diglucoside, 5 parts of syringaresinol, 10 parts of agaric polysaccharide, 5 parts of gamma-aminobutyric acid, 1 part of manninotriose and 5 parts of bergamoolide.
The preparation method of the agaric polysaccharide comprises the following steps:
(1) cleaning Auricularia, soaking, homogenizing, extracting with distilled water at 80 deg.C for 30min, boiling for 2 hr, and filtering to obtain primary extractive solution and residue;
(2) adding distilled water into the filter residue, and performing ultrasonic extraction for 60min with ultrasonic power of 80W to obtain secondary extract;
(3) mixing the primary and secondary extractive solutions, concentrating under reduced pressure, and precipitating with ethanol; preparing alcohol precipitate;
(4) dissolving the alcohol precipitate in water, treating the alcohol precipitate by sephadexG-100 gel column, eluting by using ethyl acetate, collecting ethyl acetate eluent, eluting by using distilled water, and collecting distilled water eluent; adding distilled water into ethyl acetate eluate for extraction, mixing the separated water phase with distilled water eluate, and concentrating to obtain Auricularia polysaccharide.
The preparation method of the composition containing pinoresinol diglucoside comprises the following steps:
dissolving gamma-aminobutyric acid in 200 parts of distilled water, adding a mixture of 3:1 propylene glycol and polyethylene glycol laurate (M is 1000) as a solubilizer, wherein the mass concentration of the solubilizer in the distilled water is 1%, and then dispersing pinoresinol diglucoside, syringaresinol, agaric polysaccharide, manninotriose and bergapten in the distilled water to prepare a mixed solution of the composition.
Comparative example 1
The only difference compared to example 1 was the replacement of the auricularia auricula polysaccharide with an equal amount of gamma-aminobutyric acid.
The composition containing pinoresinol diglucoside comprises the following components in parts by weight:
13 parts of pinoresinol diglucoside, 4 parts of syringaresinol, 11 parts of gamma-aminobutyric acid, 5 parts of manninotriose and 11 parts of bergapten.
The preparation method of the composition containing pinoresinol diglucoside comprises the following steps:
dissolving gamma-aminobutyric acid in 200 parts of distilled water, adding a mixture of 2:1 propylene glycol and polyethylene glycol laurate (M is 800) as a solubilizer, wherein the mass concentration of the solubilizer in the distilled water is 2%, and then dispersing pinoresinol diglucoside, syringaresinol, manninotriose and bergamoside lactone in the distilled water to prepare a mixed solution of the composition.
Comparative example 2
The only difference compared to example 1 was the use of the same amount of auricularia auricula polysaccharide instead of gamma-aminobutyric acid.
The composition containing pinoresinol diglucoside comprises the following components in parts by weight:
13 parts of pinoresinol diglucoside, 4 parts of syringaresinol, 11 parts of agaric polysaccharide, 5 parts of manninotriose and 11 parts of bergapten.
The preparation method of the auricularia auricula polysaccharide is the same as that of the example 1.
The preparation method of the composition containing pinoresinol diglucoside comprises the following steps:
taking 200 parts of distilled water, adding a mixture of 2:1 propylene glycol and polyethylene glycol laurate (M is 800) as a solubilizer, wherein the mass concentration of the solubilizer in the distilled water is 2%, and then dispersing pinoresinol diglucoside, syringaresinol, auricularia auricula polysaccharide, manninotriose and bergamoside lactone in the distilled water to prepare a mixed solution of the composition.
Comparative example 3
The only difference compared to example 1 was the use of the same amount of icariin instead of syringaresinol.
The composition containing pinoresinol diglucoside comprises the following components in parts by weight:
13 parts of pinoresinol diglucoside, 4 parts of icariin, 8 parts of agaric polysaccharide, 3 parts of gamma-aminobutyric acid, 5 parts of manninotriose and 11 parts of bergamoolide.
The preparation method of the auricularia auricula polysaccharide is the same as that of the example 1.
The preparation method of the composition containing pinoresinol diglucoside comprises the following steps:
dissolving gamma-aminobutyric acid in 200 parts of distilled water, adding a mixture of 2:1 propylene glycol and polyethylene glycol laurate (M is 800) as a solubilizer, wherein the mass concentration of the solubilizer in the distilled water is 2%, and dispersing pinoresinol diglucoside, icariin, auricularia auricular polysaccharide, manninotriose and bergamoside lactone in the distilled water to prepare a mixed solution of the composition.
Comparative example 4
Compared with example 1, the difference is only the preparation method of the auricularia auricula polysaccharide.
A composition containing pinoresinol diglucoside was prepared as in example 1.
The preparation method of the agaric polysaccharide comprises the following steps:
(1) cleaning Auricularia, soaking, homogenizing, extracting with distilled water at 70 deg.C for 40min, boiling for 1.5 hr, filtering, directly performing ultrasonic treatment for 50min at ultrasonic power of 80W, and filtering to obtain extractive solution and residue;
(2) concentrating the extractive solution under reduced pressure, and precipitating with ethanol; preparing alcohol precipitate;
(4) dissolving the alcohol precipitate in water, treating the alcohol precipitate by sephadexG-100 gel column, eluting by using ethyl acetate, collecting ethyl acetate eluent, eluting by using distilled water, and collecting distilled water eluent; adding distilled water into ethyl acetate eluate for extraction, mixing the separated water phase with distilled water eluate, and concentrating to obtain Auricularia polysaccharide.
The preparation method of the composition containing pinoresinol diglucoside is the same as that of example 1.
Comparative example 5
The only difference compared to example 1 is the solubility promoter.
A composition containing pinoresinol diglucoside was prepared as in example 1.
The preparation method of the agaric polysaccharide comprises the same steps as example 1.
The preparation method of the composition containing pinoresinol diglucoside comprises the following steps:
dissolving gamma-aminobutyric acid in 200 parts of distilled water, adding propylene glycol as a solubilizer, wherein the mass concentration of the solubilizer in the distilled water is 2%, and dispersing pinoresinol diglucoside, syringaresinol, agaric polysaccharide, manninotriose and bergapten in the distilled water to prepare a mixed solution of the composition.
Evaluation of Effect
Rat osteoporosis model: 100 SPF-grade female rats of 3.5 months old are taken, the weight of the rats is 250 +/-20 g, the rats are fed with standard pellet feed at the room temperature of 20-25 ℃, the rats contain 1 percent of calcium and 0.74 percent of phosphorus, the rats are freely fed with food and water, and the experiments are carried out after the rats are adaptively fed for 7 days. Rats were randomly divided into 10 groups, which were a model group, examples 1-3 groups, comparative examples 1-5 groups, and a blank control group.
Wherein, the model group: methylprednisolone 3.5mg/kg/d is injected subcutaneously 1 time a day. Examples 1-3 and comparative examples 1-5 groups: the mixed solution of the composition prepared by the corresponding group of the gavage is 10mg/kg/d (according to the effective content) at the same time of injecting 3.5mg/kg/d of methylprednisolone subcutaneously, and is 1 time a day. Blank control group: 3.5mg/kg/d of physiological saline was injected subcutaneously 1 time a day. Three experiments were performed simultaneously for 8 weeks with 1 dose per week, and the doses were adjusted according to body weight.
After 8 weeks, the bone density of the rats in the model group and the rats in the control group are respectively measured, and the statistical analysis that P is less than 0.05 shows that the osteoporosis model is successfully prepared. After fasting for 1 day, aortic blood was taken, serum was separated, serum osteocalcin (BGP) (kit selected from enzyme-linked organisms) was measured by radioimmunoassay, hip joint bone density (BMD) (EXPERT model manufactured by LUNAR corporation, usa) was measured by using a small animal software dedicated to a dual-energy X-ray bone densitometer, and the test results are shown in table 1.
Table 1 test results data
Note: significant differences (P < 0.05) were indicated between different letters in the same list.
The experimental data show that the model group has significant difference compared with the blank control group, which indicates that the molding is successful; the groups 1 to 3 have significant differences compared with the model group, which shows that the composition provided by the invention can effectively prevent osteoporosis. Secondly, the groups of examples 1 to 3 have significant differences from the groups of comparative examples 1 to 5, which shows that the composition of the present invention and the preparation method thereof have a great influence on the efficacy of treating osteoporosis.
The above detailed description is specific to one possible embodiment of the present invention, and the embodiment is not intended to limit the scope of the present invention, and all equivalent implementations or modifications without departing from the scope of the present invention should be included in the technical scope of the present invention.
Claims (10)
1. A composition containing pinoresinol diglucoside comprises the following components:
pinoresinol diglucoside, syringaresinol, Auricularia polysaccharide, gamma-aminobutyric acid, manninotriose and bergamotol lactone.
2. The pinoresinol diglucoside-containing composition according to claim 1, comprising the following components in parts by weight:
10-20 parts of pinoresinol diglucoside, 1-5 parts of syringaresinol, 5-10 parts of agaric polysaccharide, 1-5 parts of gamma-aminobutyric acid, 1-10 parts of manninotriose and 5-15 parts of bergamoolide.
3. The pinoresinol diglucoside-containing composition according to claim 1, comprising the following components in parts by weight:
12-16 parts of pinoresinol diglucoside, 3-5 parts of syringaresinol, 7-9 parts of agaric polysaccharide, 2-4 parts of gamma-aminobutyric acid, 4-8 parts of manninotriose and 10-12 parts of bergamoolide.
4. The pinoresinol diglucoside-containing composition according to any one of claims 1 to 3, wherein the agaric polysaccharide is prepared by:
(1) cleaning Auricularia, soaking, homogenizing, extracting in distilled water, and filtering to obtain primary extractive solution and residue;
(2) adding distilled water into the filter residue, and performing ultrasonic extraction to obtain a secondary extracting solution;
(3) mixing the primary and secondary extractive solutions, concentrating under reduced pressure, and precipitating with ethanol; preparing alcohol precipitate;
(4) dissolving the alcohol precipitate in water, treating the alcohol precipitate by sephadexG-100 gel column, eluting by using ethyl acetate, collecting ethyl acetate eluent, eluting by using distilled water, and collecting distilled water eluent; adding distilled water into ethyl acetate eluate for extraction, mixing the separated water phase with distilled water eluate, and concentrating to obtain Auricularia polysaccharide.
5. The pinoresinol diglucoside-containing composition according to claim 4, wherein in the step (1), the extraction is performed for 1-2h by boiling extraction after 30-60min at 60-80 ℃; in the step (2), the power of the ultrasound is 80-100W; the extraction time is 30-60 min.
6. A process for the preparation of a pinoresinol diglucoside-containing composition according to any one of claims 1 to 5, comprising the steps of:
dissolving gamma-aminobutyric acid in distilled water, adding solubilizer, and dispersing pinoresinol diglucoside, syringaresinol, Auricularia polysaccharide, mannotriose, and bergamoolide in distilled water to obtain mixture.
7. The method of claim 6, wherein the solubilizer is any one or more of propylene glycol, polyethylene glycol laurate and polyethylene glycol glyceryl stearate.
8. The method of claim 7, wherein the solubilizer is a mixture of propylene glycol and polyethylene glycol laurate, wherein the propylene glycol and polyethylene glycol laurate are present in a mass ratio of 1-3: 1; the relative molecular weight of the polyethylene glycol laurate is 600-1000; the mass concentration of the solubilizer in distilled water is 1-5%.
9. Use of a composition comprising pinoresinol diglucoside according to any one of claims 1 to 5 or a composition comprising pinoresinol diglucoside according to any one of claims 6 to 8, which is prepared by the method for preparing the composition, for preparing a medicament for preventing and treating osteoporosis.
10. A pharmaceutical preparation comprising the composition containing pinoresinol diglucoside according to any one of claims 1 to 5 or the composition containing pinoresinol diglucoside according to any one of claims 6 to 8, and pharmaceutically usual excipients.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110733999.0A CN113413395A (en) | 2021-06-30 | 2021-06-30 | Composition containing pinoresinol diglucoside and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110733999.0A CN113413395A (en) | 2021-06-30 | 2021-06-30 | Composition containing pinoresinol diglucoside and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113413395A true CN113413395A (en) | 2021-09-21 |
Family
ID=77717210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110733999.0A Pending CN113413395A (en) | 2021-06-30 | 2021-06-30 | Composition containing pinoresinol diglucoside and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113413395A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114716491A (en) * | 2021-11-25 | 2022-07-08 | 广西民族大学 | Three compounds derived from Tougo lignin, and preparation method and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101181469A (en) * | 2007-11-26 | 2008-05-21 | 沈阳药科大学 | Osteosporosis-resistance chinese medicine extract as well as extracting technique and usage of active component |
| CN101647850A (en) * | 2009-09-07 | 2010-02-17 | 天津中医药大学 | New application of chemical component of eucommia bark used as plant estrogen |
| CN101703561A (en) * | 2009-10-13 | 2010-05-12 | 肖军平 | Eucommia bark effective position for treating osteoporosis and preparation method thereof |
| CN103819518A (en) * | 2014-03-05 | 2014-05-28 | 吉首大学 | Preparation method for standardized extracts of eucommia ulmoides pinoresinol diglucoside |
| CN104490908A (en) * | 2014-11-28 | 2015-04-08 | 普正药业股份有限公司 | Pharmaceutical composition derived from eucommia ulmoides and use of pharmaceutical composition |
| CN106036314A (en) * | 2016-06-06 | 2016-10-26 | 山东水晶生物科技股份有限公司 | Oral liquid containing gamma-aminobutyric acid |
| CN109602733A (en) * | 2018-12-19 | 2019-04-12 | 泓博元生命科技（深圳）有限公司 | Improve the composition and the preparation method and application thereof of osteoporosis |
| CN111686147A (en) * | 2020-06-28 | 2020-09-22 | 江西普正制药股份有限公司 | Eucommia ulmoides extract and application thereof in treating osteoporosis |
-
2021
- 2021-06-30 CN CN202110733999.0A patent/CN113413395A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101181469A (en) * | 2007-11-26 | 2008-05-21 | 沈阳药科大学 | Osteosporosis-resistance chinese medicine extract as well as extracting technique and usage of active component |
| CN101647850A (en) * | 2009-09-07 | 2010-02-17 | 天津中医药大学 | New application of chemical component of eucommia bark used as plant estrogen |
| CN101703561A (en) * | 2009-10-13 | 2010-05-12 | 肖军平 | Eucommia bark effective position for treating osteoporosis and preparation method thereof |
| CN103819518A (en) * | 2014-03-05 | 2014-05-28 | 吉首大学 | Preparation method for standardized extracts of eucommia ulmoides pinoresinol diglucoside |
| CN104490908A (en) * | 2014-11-28 | 2015-04-08 | 普正药业股份有限公司 | Pharmaceutical composition derived from eucommia ulmoides and use of pharmaceutical composition |
| CN106036314A (en) * | 2016-06-06 | 2016-10-26 | 山东水晶生物科技股份有限公司 | Oral liquid containing gamma-aminobutyric acid |
| CN109602733A (en) * | 2018-12-19 | 2019-04-12 | 泓博元生命科技（深圳）有限公司 | Improve the composition and the preparation method and application thereof of osteoporosis |
| CN111686147A (en) * | 2020-06-28 | 2020-09-22 | 江西普正制药股份有限公司 | Eucommia ulmoides extract and application thereof in treating osteoporosis |
Non-Patent Citations (10)
| Title |
|---|
| 余元勋，著: "《中国分子中药学》", 30 June 2017, 安徽科学技术出版社 * |
| 吴思敏，等: "松脂醇二葡萄糖苷促进体外培养成骨细胞骨形成的作用研究", 《解放军医药杂志》 * |
| 李明凯，等主编: "《香豆素整合药学研究》", 30 June 2018, 科学技术文献出版社 * |
| 林芳: "杜仲治疗骨质疏松的有效成分筛选及质量控制的研究", 《中国优秀博硕士学位论文全文数据库(硕士)医药卫生科技辑》 * |
| 梁光义，主编: "《中药化学》", 31 July 1998, 人民卫生出版社 * |
| 潘亚磊，等: "杜仲松脂醇二葡萄糖苷的提取工艺优化", 《化学与生物工程》 * |
| 田英杰，等: "γ-氨基丁酸改善高脂膳食小鼠的骨性能", 《食品与生物技术学报》 * |
| 罗伟，等: "杜仲抗骨质疏松及其机制研究进展", 《中国临床药理学与治疗学》 * |
| 胡倩影，等: "杜仲中松脂素二葡萄糖苷和松脂素对成骨细胞中OPG和RANKL表达的影响", 《中国实验方剂学杂志》 * |
| 马力，主编: "《食品化学与营养学》", 30 September 2007, 中国轻工业出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114716491A (en) * | 2021-11-25 | 2022-07-08 | 广西民族大学 | Three compounds derived from Tougo lignin, and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115381747B (en) | Anti-drop composition, preparation method and application | |
| CN1262267C (en) | Speckle removing and whitening traditional medicinal healthy product and its preparation | |
| CN111686147A (en) | Eucommia ulmoides extract and application thereof in treating osteoporosis | |
| CN1168279A (en) | Glossy ganoderma-Eighteen treasure oral liquid | |
| CN113413395A (en) | Composition containing pinoresinol diglucoside and preparation method and application thereof | |
| CN111686209A (en) | Traditional Chinese medicine compound preparation for treating Parkinson's disease and preparation method and application thereof | |
| CN1840128A (en) | Medicine for treating cardiovascular disease | |
| CN1209133C (en) | Medicine for preventing and curing rachitis and osteoporosis and method for preparing the same | |
| CN103405755B (en) | Pharmaceutical composition for treating primary osteoporosis | |
| CN101396528A (en) | Traditional Chinese medicine composite preparation for treating wind-heat cold | |
| CN115040610A (en) | Composition and preparation for reducing blood pressure and preparation method | |
| CN102114070B (en) | Compound traditional Chinese medicine for treating osteoporosis and preparation method thereof | |
| CN101703561A (en) | Eucommia bark effective position for treating osteoporosis and preparation method thereof | |
| CN1611232A (en) | Medicinal composition with main effect of antifatigue, radioresistance and melancholia-resistance and its preparing method | |
| CN114903961A (en) | Composition for treating osteoarthropathy and application thereof | |
| CN111643540A (en) | Eucommia ulmoides extract for treating lumbar muscle strain and preparation method thereof | |
| CN109876127B (en) | Blood-nourishing angelica sinensis capsule and preparation method thereof | |
| CN114712489A (en) | Composition for relieving bone and joint pain and preparation method and application thereof | |
| CN116832103B (en) | Preparation process of tendon-relaxing and collateral-strengthening oil | |
| CN108143800B (en) | Traditional Chinese medicine composition for treating hypertensive heart failure | |
| CN105853689A (en) | Application of green plum extract to preparation of health care product for treating osteoporosis | |
| CN106880654B (en) | Application of panax japonicus extract in preparing medicine for treating rhinitis and composition | |
| CN1051464C (en) | Oral medicine for curing seborrheic baldness | |
| CN112755137B (en) | Traditional Chinese medicine composition for treating mild and moderate knee osteoarthritis and application thereof | |
| CN1375320A (en) | Chinese medicine for treating hyperosteogeny and its prepn. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210921 |
|
| RJ01 | Rejection of invention patent application after publication |